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Nerve growth factor (NGF) plays a crucial role in the life of the sympathetic and sensory nervous 
systems. However, the roles of NGF to cervical cancer remain deeply unknown. This study investigated 
the effect of recombinant human nerve growth factor (rhNGF) on cervical cancer. It was found that the 
proliferation of hela cells was inhibited by rhNGF and there were some apoptotic-like cell deaths. After 
tumor modeling of mice implanted U14 cells, it was shown that the growth of tumor tissues was 
inhibited in response to rhNGF and the concentration of virus been rhNGF was not more than 1.0×10
7 
pfu/ml. In addition, the immune abilities of thymus and spleen were improved by rhNGF. Finally, it was 
shown that SOD level of tumor tissues was improved under the right concentration of rhNGF. 
Therefore, the mentioned result showed that cervical cancer is probably treated by rhNGF, which is 
depended on the concentration of rhNGF. 
 





Nerve growth factor (NGF), an evolutionarily conserved 
polypeptide neurotrophin, plays a crucial role in the life of 
the sympathetic and sensory nervous systems (Sofroniev 
et al., 2001). The biologic effects of NGF on neural cells 
are mediated by 2 different receptor classes; the 
tropomyosin-related kinase A (TrkA) of tyrosine kinase 
receptor and the neurotrophin receptor p75, a member of 
the tumor necrosis factor receptor family (Frade and 
Barde, 1998; Frade et al., 1996; Rabizadeh et al., 1993; 
Wang et al., 2001). The binding of NGF to TrkA receptor 
promotes cell survival. When NGF binds to TrkA, it 
phosphorylates TrkA, which leads to the activation of PI 3 
Kinase, ras and PLC signaling pathways. However, NGF 
binding to p75 receptor triggers cell apoptosis (Park  et 
al., 2007). P75NTR induces apoptosis through its death 
domain in a NGF-independent manner and Caspases 9, 





*Corresponding author. E-mail: ysulqw@126.com (Q.-W. Li). 
Tel: +86 29 87092102. Fax: +86 29 87092164. 
 
# Co-first authors. 
When p75NTR is activated by NGF, the activation of 
p75NTR kills cells in the  central  nervous  system  during 
normal development (Frade and Barde, 1998). The 
simultaneous expression of both receptors promotes cell 
proliferation, as the survival-enhancing effects of TrkA 
receptor negate the apoptosis-inducing signals of p75 
receptor. The precise ratio of TrkA and p75 receptors is 
thought to be an important determinant of cell survival 
and death (Arrighi et al., 2010). 
At present, there are many reports on NGF in neo-
plasms unrelated to the nervous system (Fanburg-Smith 
and Miettinen,  2001), such as myeloma, acute myeloid 
leukemia, fibrosarcoma, hepatocellular carcinoma, pan-
creatic cancer, lung cancer and thyroid papillary 
carcincoma (Eguchi et al., 1999; Knezevich et al., 1998;  
McGregor et al., 1999; Okada et al., 2004; Pearse et al., 
2005; Ricci et al., 2001; Yang et al., 2005). Bothwell 
(1991)
 
reported that TrKA was the producer of oncogene. 
Dollé et al. (2003)
 
proved that, NGF was the promoter of 
breast cancer. Adriaenssens et al.
 
(2008) showed that 
NGF was the new target for breast cancer treatment. 
However, other reports showed that cell death was 
induced by NGF through its p75 receptor (Frade et al., 
1996; Rabizadeh et al., 1993). Missale et al.
 
(1993) 
reported that NGF suppressed the transforming phenol- 




type   of   human  prolactinomas  and  NGF  could  cause  
differentiation of rat C6 glioma cells and strongly inhibit 
their proliferation in vitro (Kimura et al., 2002). Although, 
the effect of NGF on the cancer possibly depends on the 
tumor types (Krüttgen et al., 2006), the detailed role of 
NGF to tumor cells is still not clear and controversial. This 
study was aimed to detect the effect of NGF on cervical 
cancer. It was shown that the proliferation of cervical 
cancer cells was inhibited by rhNGF in vitro and in vivo; 
whereas the action was related to the concentration of 
rhNGF. In addition, it was found that the immunity of 
cervical cancer mice was improved. 
 
 




MTT and Trypanblau were from Sigma. Hoechst was purchased 
from Biyuntian biotechnology research center. 5-fluorouracil was 
purchased from Jinyao amino acid Inc. (Tianj in, China) and 50 
µg/ml with normal sodium was made when needed. CTX (Cyclo-
phosphamide, Batch no. H14020373) was purchased from 
Taisheng drugs manufacture (Shanxi, China) and 100 mg/L was 
made with normal sodium when needed for use. Unless otherwise 
specified, all the chemicals were purchased from China. 
 
 
RhNGF, 293T cells, hela cells, U14 cells and animals 
 
RhNGF was a gift from the Biotechnology Laboratory of Yanshan 
University, Qinhuangdao, China. 293T cells, hela cells and mouse 
UCC U14 cell lines were from the Institute of Materia Medica of 
Chinese Academy of Medical Sciences. Kunming cleaning female 
mice (Lic No. SCXK (capital) 2004-0001) were from the Institute of 
Zooscopy of Chinese Academy of Medical Sciences. The test 
temperature of the mice was 20 to 25°C and the relative humidity 
was 40 to 60%. 
 
 
Cell culture and the effect of rhNGF on hela cells  
 
293T cells infected GFP-rhNGF virus were grown at 37°C in 
Dulbecco’s modified eagle’s medium (DMEM) containing 10% FBS 
and maintained in a 5% CO2 atmosphere. When the rate of 
cytopathic effect (CPE) was up to 90%, the cells were collected, 
lysated and centrifugated. After that, the supernatant was collected 
to detect the concentration of GFP-rhNGF virus.  
The inhibition rate of hela cells was detected by MTT. Six 
experimental groups were prepared; negative control group, 
positive control group and 4 rhNGF-treated groups. Each group 
was inoculated with about 1.0×10
4 
pfu hela cells. After the hela cells 
were cultured for 24 h, GFP-rhNGF virus was added and the 








pfu/ml, respectively. The medium was added into the 
cells of the negative control group and 5-fluorouracil was added 
into the cells of the positive control group. The hela cells were 
incubated for 24 h again, 0.1 mg MTT was added to each group 
and then, the cells were cultured for 4 h. After that, the old medium 
was removed and 150 µl DMSO was added. Finally, the OD value 
was determined at less than 492 nm through ELISA reader, to 
count the cell inhibition rate.  
The cell apoptosis was checked by Hoechst. Hela cells of the 
rhNGF-treated groups (1.0×10
7 
pfu/ml) were incubated for 24 and48 





with PBS and 100 µ and Hoechst  was  added.  After  staining for 
20 min, the cells were observed and photographs were taken. 
 
 
Mouse U14 cells modeling and analyzing 
 
The fasted (one-day) and weighted mice were implanted with about 
1.5×10
6
 pfu U14 cells and were left forefoot oxter. After that, the 
mice were randomly divided into 6 groups which included a 
negative and a positive control group and 4 rhNGF-treated groups. 
Each group had 8 mice. The following day, all the mice in the 
negative control group were given 0.2 ml distilled water and all mice 
of the positive control group were given 1 mg of CTX per 10 g wt. 









 pfu, respectively. The treatment to 
the mice was given once per day for 15 days. After the 
discontinuation, mice were weighted and then, sacrificed to 






All experiments were repeated at least two times. Results were 
expressed as mean ± S.E. The data were analyzed with the 






Effect of rhNGF on hela cells  
 









 pfu/ml) were firstly in turn named 
rhNGF-1, rhNGF-2, rhNGF-3 and rhNGF-4 respectively 
for convenient records. According to Figure 1, the 
proliferation of hela cells was inhibited by rhNGF. The 
inhibition rate gradually went up with the increase of 
GFP-rhNGF virus concentration. When the concentration 
of GFP-rhNGF virus reached 1.0×10
7 
pfu/ml, the 
inhibitory action of rhNGF to hela cells was increased 
greatly and the inhibition rate was 72.63%. However, the 
inhibitory action on the basis of rhNGF-3 group was not 
improved when the concentration of rhNGF virus 
surpassed 1.0×10
7 
pfu/ml. Therefore, it was concluded 
that the proliferation of hela cells was inhibited in 
response to rhNGF and the inhibitory action was best 





RhNGF induces the apoptosis of hela cells  
 
The apoptosis of hela cells was detected through 
Hoechst. Cell nucleus was stained blue. Apoptotic body 
was not found when hela cells of the negative control 
group were cultured for 48 h. However, some apoptotic 
bodies were observed when rhNGF-treated cells (1.0×10
7 
pfu/ml) were cultured for 24 h and more apoptotic bodies 
were seen after 48 h (Figure 2b,c). Therefore, it was 
speculated that cell apoptosis was developed in response 
to  rhNGF  and  the  changes  were  increasingly  obvious  
 
 





Figure 1. The proliferation of hela cells blocked by rhNGF. The cytostasis rate was the 
percentage of the OD value of the negative control group which minus the OD value of 
the drug-treated group divided by the OD value of the negative control group (×100). 
Through Elisa reader, OD values of all the experimental groups were obtained and the 
cytostasis rate of hela cells was counted. The cytostasis rate in the positive, rhNGF-1, 
rhNGF-2, rhNGF-3 and rhNGF-4 groups were 52.01, 56.06, 60.83, 72.63 and 72.52%, 
respectively. Values with different letter showed significant discrepancy (P < 0.05) and 






Figure 2. Cell apoptosis detected through Hoechst. Hela cell nucleus was stained blue. In the negative control group, 
there were no apoptotic bodies (A). However, there were some apoptotic bodies in rhNGF-3 group when hela cells 




with the time extending.  
 
 
Inhibition of rhNGF to mouse tumors 
 
In this experiment, tumor inhibitory rate of rhNGF-3 group 
was 50.89% and almost reached the result of the positive 
group (P > 0.05). When the concentration of rhNGF virus 
was less than 1×10
7 
pfu/ml, the tumor inhibitory rate went 
up with the increase of rhNGF concentration, which 
showed that the tumor was significantly inhibited. How-
ever, when the concentration of rhNGF virus reached 
1.0×10
8 
pfu/ml, the tumor inhibitory rate dropped greatly 
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Figure 3. Effect of rhNGF on tumors of mice. Tumor inhibitory rate for all the test groups 
was counted and they were 59.95% for CTX group, 15.32% for rhNGF-1 group, 23.86% for 
rhNGF-2 group, 50.89% for rhNGF-3 group and -0.13% for rhNGF-4 group, respectively. 
Values with different letter showed significant discrepancy (P < 0.05) and same letter 




not inhibited (Figure 3). Therefore, it was shown that the 
inhibition of tumor was best when the concentration of 





Changes of spleen and thymus in response to rhNGF  
 
To know the effect of rhNGF on animal immune function, 
the thymus and spleen were investigated. It was found 
that the qualities of thymus and spleen in cervical cancer 
mice were normal. The indexes of thymus and spleen 
greatly went up in response to rhNGF when compared 
with the negative control group (Figure 4, P < 0.05). The 
stated results showed that the immunity of mice was 
imported by rhNGF. 
 
 
SOD level in response to rhNGF  
 
SOD is a defensive enzyme of organisms and it catalyses 
the conversion of O2 to H2O2 and the latter again forms 
nontoxic H2O under the action of peroxydase so that free 
radicals which result in tumorigenesis are completely 
cleared (Breimer, 1990; Dizdaroglu et al., 2002; Vaca et 
al., 1988; Yang and Fu, 2001). In this experiment, except 
for rhNGF-4 group, the SOD levels of tumor organs in the 
other rhNGF groups were greatly improved when 
compared with the negative group, but they were less 
than that of the positive group (P < 0.05). Significantly, 
SOD level of tumor organs greatly went down instead 





pfu/ml (Figure 5).   
 
 
Effect of rhNGF on cervical cancer 
 
The direct action of rhNGF to cancer was determined 
through the inhibitory rates of cancer cells in vitro and in 
vivo. The effect of rhNGF on mouse immunity was 
showed through the indexes of spleen and thymus and 
free radicals were cleared, which indicated the treatment 
of SOD to cancer. From Figure 6, it can be seen that, the 
anti-cancer action of rhNGF was depended on its 
concentration. When the concentration of GFP-rhNGF 
virus was less than 1.0×10
7 
pfu/ml, tumor inhibition, 
mouse immunity and SOD level were improved. Never-
theless, the anti-cancer action went down when the 
concentration of GFP-rhNGF virus surpassed 1.0×10
7 
pfu/ml. Therefore, it was concluded that rhNGF had 
positive correlation with the inhibition of cervical cancer 








In this study, it was shown that the cells of cervical cancer 
were inhibited in response to rhNGF and the immunity of 
mice and SOD of tumor organs were improved. Never-
theless, the anticancer roles were depended on the 
concentration of the GFP-rhNGF virus.  


































Figure 4. Spleen and thymus of cervical cancer mice affected by rhNGF. Mouse spleen 
indexes were 112.5 mg for the negative control group, 114.1 mg for positive control 
group, 129.1 mg for rhNGF-1 group, 136.4 mg for rhNGF-2 group, 139.1 mg for rhNGF-3 
group, 144.9 mg for rhNGF-4 group per 10 g wt, respectively (A) and mouse thymus 
indexes were 8.8 mg for the negative control group, 9.0 mg for the positive control group, 
12.0 mg for rhNGF-1 group, 13.1 mg for rhNGF-2 group, 21.7 mg for rhNGF-3 group and 
18.7 mg for rhNGF-4 group per 10 g wt, respectively (B). Values with different letter 




Was affected by rhNGF (Zhang et al., 2003). In this 
experiment, rhNGF was used to treat hela cells and the 
tumors resulted from U14 cells. It was found that the cell 
proliferation was inhibited in response to rhNGF and the 
inhibitory action gradually went up with the increase of 
rhNGF when the concentration of GFP-rhNGF virus was 
not more than 1.0×10
7 
pfu/ml. This showed that, rhNGF 
greatly bound p75NTR because p75NTR induces cell 
death (Park  et al., 2007). Nevertheless, when the con-
centration of GFP-rhNGF virus was more than 1.0×10
7 
pfu/ml, the anti-cancer action of rhNGF greatly went 
down instead. Since the binding of NGF to the TrkA 
receptor promotes cell survival (Bothwell, 1991), it was 
considered that rhNGF could have greatly bound TrkA on 
the high dosage of rhNGF which resulted in the cell 
proliferation and the  anti-cancer action was lost. Certainly,    






Figure 5. SOD level in tumor-bearing mice was investigated through biochemical 
experiments. SOD levels of tumor organs in cervical cancer mice were 0.1170 U/mgprot of 
negative control group, 0.2083 U/mgprot of CTX group, 0.1557 U/mgprot of rhNGF-1 group, 
0.1602 U/mgprot of rhNGF-2 group, 0.1909 U/mgprot of rhNGF-3 group and 0.1259 
U/mgprot of rhNGF-4 group, respectively. Values with different letter showed significant 






Figure 6. Cell inhibitory rate, tumor inhibitory rate, spleen index, thymus 
index and SOD level of tumor tissue in response to rhNGF. When the 
concentration of rhNGF virus was less than 1.0×10
7 
pfu/ml, rhNGF had 
positive correlation with inhibitory rate of cell proliferation, tumor inhibition, 







the detailed mechanism should be studied further. 
Report showed that NGF has a significant role in the 
nerve, endocrine and immune system (Miao et al., 2006). 
Since the mentioned experiments showed that the 
proliferation of cancer cells was inhibited by rhNGF, the 
immune organs were possibly involved in the process 
because they were related with the tumor inhibition. 
Therefore, thymus and spleen were investigated to check 
the reaction of mouse immune function in response to 
rhNGF. It was shown that, thymus and spleen weights 
were added and rhNGF groups had obvious discrepancy 
in comparison with the negative control group (P < 0.05). 
Spleen contains many T cells which possibly kill tumor 
cells. Because the spleen weight of rhNGF groups was 
enhanced, it was suggested that the immunity of the 
tumor-bearing mice was improved. The above results 
were consistent with that of Klaus et al. (Knezevich et al., 
1998).
 
Next, it was found that the content of SOD got to 
the highest point when the concentration of rhNGF virus 
reached 1.0×10
7 
pfu/ml. However, when the 
concentration of rhNGF virus was more than 1.0×10
7 
pfu/ml, the content of SOD went down which maybe the 
reason why the tumor cells of rhNGF-4 group were not 
inhibited. As such, the content of SOD was improved 
under the right concentration of rhNGF, which helped in 
the treatment of cervical cancer. 
In summary, rhNGF had inhibitory action on cervical 
cancer in which cell apoptosis was developed and mouse 
immunity was improved. However, there are still some 
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